Abstract
Vaccines require optimal adjuvants including immunopotentiator and delivery systems to offer long term protection from infectious diseases in animals and man. Initially it was believed that adjuvants are responsible for promoting strong and sustainable antibody responses. Now it has been shown that adjuvants influence the isotype and avidity of antibody and also affect the properties of cell-mediated immunity. Mostly oil emulsions, lipopolysaccharides, polymers, saponins, liposomes, cytokines, ISCOMs (immunostimulating complexes), Freund’s complete adjuvant, Freund’s incomplete adjuvant, alums, bacterial toxins etc., are common adjuvants under investigation. Saponin based adjuvants have the ability to stimulate the cell mediated immune system as well as to enhance antibody production and have the advantage that only a low dose is needed for adjuvant activity. In the present study the importance of adjuvants, their role and the effect of saponin in immune system is reviewed.
Keywords: Adjuvants, Saponins, Immunity, Immunostimulators, Steroids, Triterpenoid
INTRODUCTION
Infectious diseases have always been a scourge to human beings and their companion animals. Many infectious diseases are ubiquitous and often fatal. Vaccination is the most efficacious and valuable tool in the prevention of infectious diseases, provided that they are administered prophylactically in anticipation of pathogen exposure. Vaccines mainly capitalize the immune system’s ability to respond rapidly to microorganisms after a second encounter and have been described as ‘weapons of mass protection’ (Cohen and Marshall, 2001; Curtiss, 2002). The goal of vaccination is to stimulate a strong, protective and long-lasting immune response to the administered antigen. For the achievement of these objectives, potent adjuvant and novel vaccine strategies are required to make the vaccine sufficiently immunogenic to initiate a potent immune response (Fearon, 1997; Bomford, 1998). Saponin based adjuvants have the unique ability to enhance immunity.
IMPORTANCE OF VACCINE ADJUVANT
Adjuvants
The word adjuvant is derived from the Latin word adjuvare, which means help or aid or to enhance (Vogel, 1998). Singh and O′Hagan (2003) reviewed that immunological adjuvants were originally described by Ramon in 1924 as “substances used in combination with a specific antigen that produced a more robust immune response than the antigen alone”. This broad definition encompasses a very wide range of materials (Vogel and Powell, 1995). The first adjuvants were developed in the 1920’s and a number of substances including chemicals, microbial components and mammalian proteins have been used to boost the immunity (Cox and Coulter, 1992; 1997).
Importance of adjuvants
These are a group of structurally heterogeneous compounds that enhance or modulate the immunogenicity of the poorly immunogenic vaccine proteins or peptides (Gupta et al., 1993; Vogel, 1995). Most vaccines traditionally consist of live attenuated pathogens, whole inactivated/killed organisms or inactivated toxins containing many immunopotentiators essential for activating integrated protective immune responses. An adjuvant can be used for increasing the immunogenicity of poor antigen, improving the efficacy of vaccine in new born and reducing the amount of antigen or the number of immunizations (McElrath, 1995). Compared to injection of antigen alone, injection of antigen plus an adjuvant generally permits use of a much smaller quantity of the antigen and greatly enhances the antibody titer (Kaeberle, 1986).
Roles of adjuvant in modulation of immune responses
Adjuvants can be used to improve the immune response to vaccine antigens for several different purposes, including: (1) increasing the immunogenicity of weak antigens; (2) enhancing the speed and duration of the immune response; (3) modulating antibody avidity, specificity, isotype or subclass distribution; (4) stimulating cell mediated immunity; (5) promoting the induction of mucosal immunity; (6) enhancing immune responses in immunologically immature or senescent individuals; (7) decreasing the dose of antigen in the vaccine to reduce costs or (8) helping to overcome antigen competition in combination vaccines (Singh and O′Hagan, 2003). Adjuvants were initially thought of as agents capable of promoting and sustaining antibody response. However, new evidence has shown that adjuvants influence the titer, duration, isotype, and avidity of antibody, and affect the properties of cell-mediated immunity (Hunter et al., 1995).
Classification of adjuvants
Different scientists used different criteria for classifying the adjuvants. Cox and Coulter (1992) classified adjuvants into particulate and non-particulate groups. According to Vogel (1998) adjuvants can be classified according to their sources, mechanism of action or physiochemical properties. Edelman [1997; reviewed by Allison and Byars (1991)] classified adjuvants into three groups: (1) immunostimulatory adjuvants, (2) carrier adjuvants and (3) vehicle adjuvants. Adjuvants are also classified: (1) according to their route of administration like mucosal or parental; (2) divided into alum salts and other mineral adjuvants, tensoactive agents, bacterial derivatives, vehicles and slow release materials or cytokines (Byars and Allison, 1990); (3) divided into the groups: gel-based adjuvants, tensoactive agents, bacterial products, oil emulsions, particulate adjuvants, fusion proteins or lipopeptides (Jennings et al., 1998).
Most common adjuvants
Mostly aluminum or oil adjuvants are used in vaccine, but these chemical adjuvants have many disadvantages, such as side effects, strong local stimulation and carcinogenesis, together with complicated preparations or failure to increase immunogenicity of weak antigen and so on (Bowersock and Martin, 1999; Gupta et al., 1995; Gong and Wu, 1996). Comparative studies in humans and animals showed that aluminum is a weak adjuvant for antibody induction to recombinant protein vaccines and induces a Th2, rather than a Th1 response (Gupta, 1998). Some other group of adjuvants including oil emulsions, lipopolysaccharides, polymers, saponins, liposomes, cytokines, ISCOMs, Freund’s complete adjuvant, Freund’s incomplete adjuvant, alums, bacterial toxins etc., have been evaluated and clinical trials are under investigation, although the mechanism of action of adjuvants often remain poorly understood (Vogel, 1995; Edelman, 1997).
EFFECTS OF SAPONINS ON ANIMAL IMMUNE SYSTEM
Saponins
Saponins are steroid or triterpenoid glycosides found in wild or cultivated plants, lower marine animals and some bacteria (Riguera, 1997; Yoshiki et al., 1998). Saponins contain a steroidal or triterpenoid aglycone to which one or more sugar chains are attached (Oda et al., 2003). These are found widely in the plant kingdom with the triterpenoid saponins predominant mostly in cultivated crops, while steroid saponins are common in plants used as herbs or for their health-promoting properties according to Fenwick et al.(1991). Triterpenoid saponins have been detected in many legumes such as soybeans, beans, peas, lucerne, etc., and also in alliums, tea, spinach, sugar beet, quinoa, liquorices, sunflower, horse chestnut and ginseng. Steroid saponins are found in oats, capsicum peppers, aubergine, tomato seed, alliums, asparagus, yam, fenugreek, yucca and ginseng. Saponins are tensoactive glycosides containing a hydrophobic nucleus of triterpenoid structure with carbohydrate chains linked to the nucleus (Kensil, 1996).
One example of an extensively studied group of triterpenoid saponins is produced from the bark of Quillaja saponaria, a tree native to the Andes region (Francis et al., 2002). Experiments demonstrating the physiological, immunological and pharmacological properties of saponins have aroused considerable clinical interest in these substances. In animal system, various studies have shown the effect of saponins on cell membrane, animal growth and feed intake, protein digestion, cholesterol metabolism, animal reproduction, the immune system, nervous system functioning or cytostatic effects on malignant cells or molluscicidal effect or virucidal activity or effect on protozoa (Francis et al., 2002).
Effects on immune system
Saponin based adjuvants have the ability to modulate the cell mediated immune system as well as to enhance antibody production and have the advantage that only a low dose is needed for adjuvant activity (Oda et al., 2000). Saponins induce a strong adjuvant effect to T-dependent as well as T-independent antigens. Saponins also induce strong cytotoxic CD8+ lymphocyte responses and potentiate the response to mucosal antigens (Kensil, 1996). However, saponins are surface active agents and cause haemolysis of red blood cells in vitro, although haemolysis does not appear to be correlated with adjuvant activity (Kensil, 1996). The study results of Oda et al.(2000) suggested that the adjuvant activity of saponins did not relate with haemolytic activity. It was considered that not only the functional groups themselves, but the overall conformation of such functional groups, affected adjuvant activity of saponins. Saponins have been widely used as adjuvants for many years and have been included in several veterinary vaccines. The adjuvant action of saponins was, however, not so pronounced in some of the non-mammalian species tested (Cossarini-Dunier, 1985; Grayson et al., 1987).
Saponin not only has stimulatory effects on the components of specific immunity, but also presents some non-specific immune reactions such as inflammation (de Oliveira et al., 2001; Haridas et al., 2001) and monocyte proliferation (Delmas et al., 2000; Yui et al., 2001).
Mechanism of action
The mechanisms of immune-stimulating action of saponins have not been clearly understood, but many explanations have been put forward. Saponins reportedly induce production of cytokines such as interleukins and interferons that might mediate their immunostimulant effects (Jie et al., 1984; Kensil, 1996). It is likely that they interact with antigen-presenting cells to induce many of these responses (Barr et al., 1998). The incorporation of saponins into cell or endosomal membranes might expose the incorporated antigen to cytosolic proteases. According to Bangham et al.(1962), saponins have been shown to intercalate into cell membranes, through interaction with cholesterol, forming ‘holes’ or pores. It is currently unknown if the adjuvant effect of saponins is related to pore formation, which may allow antigens to gain access to the endogenous pathway of antigens presentation, promoting cytotoxic T-lymphocyte (CTL) response (Sjölander et al., 2001).
It was believed that the adjuvant activity of saponins could be related to branched sugar chains or aldehyde groups (Bomford et al., 1992) or to an acyl residue bearing the aglycone (Kensil, 1996). Latter, soyasaponins and lablabosides were found to show strong adjuvant activity despite lacking acyl residues and possessing only un-branched sugar chains (Oda et al., 2000). Also, most of the escins that have acyl residues and branched sugar chains did not show adjuvant activity. Adjuvant activity and toxicity, but not the cholesterol-binding capacity, of QH-B, a Quillaja fraction, decreased on peroxidate oxidation due to alterations in the structure of the sugars, galactose and xylose. Modification of the apiose moiety may influence adjuvant activity but not toxicity in vivo (Ronnberg et al., 1997). Saponins with an acyl residue or oxide-ring moiety tend to show haemolytic activity (Oda et al., 2000). Oda et al.(2000) concluded that not only the functional groups themselves, but the overall conformation of such functional groups, affected adjuvant activity of saponins. Soyasaponins, lablabosides and purified Quillaja saponin-21, which possess adjuvant action, have only two to four O atoms, equally distributed around the aglycone, and may retain the typical amphipathic features. On the other hand, escins without adjuvant activity have seven O atoms, with five localized around one side of the aglycone, thus reducing its hydrophobic and adjuvant nature. In a study of structural and biological activity of protopanaxatriol-type saponins (PTS) from the roots of Panax notoginseng, Sun et al.(2006a) concluded that the number, length and position of sugar side chains, and the type of glucosyl group in the structure of PTS could not only affect their haemolytic activities and adjuvant potentials, but have significant effects on the nature of the immune responses.
Quillaja saponaria
The bark extract of the tree Quillaja saponaria was found to have adjuvant activity. The extract contains a number of components that have been purified and found to exhibit adjuvant activity, individually (Jacobsen et al., 1996). Quillaja and other saponins, either as crude mixtures or as purified compounds, have been reported to increase immune-cell proliferation in vitro (Chavali et al., 1987; Plohmann et al., 1997; Lacaille-Dubois et al., 1999). Purified Quillaja saponins boosted antibody production without producing any reaginic antibodies (So et al., 1997). Chavali and Campbell (1987a; 1987b) found that mice fed Quillaja saponins exhibited increased cell proliferation in spleen and mesenteric lymph nodes and increased and prolonged natural killer (NK) cell activity, suggesting that saponins act directly on T-helper cells of the mucosal immune system to induce secretion of soluble mediators. Other studies also suggest that Quillaja saponin has mitogenic activity and induces T cell and B cell proliferation (Chavali et al., 1987; Mowat et al., 1991).
Quil A is a saponin fraction derived from an aqueous extract from the bark of Quillaja saponaria. Fractions purified from this extract by reverse phase chromatography, mainly QS-21, have been studied as alternatives to alum when strong cellular responses are required for a particular vaccine (Allison and Byars, 1991; Kensil et al., 1991; Takahashi et al., 1990). Adjuvants that are surface-active agents rely on surface free energy of cells to bind to hydrophobic surfaces and bring about their immunostimulatory properties (Allison, 1979). Quil A and QS-21 (saponin-type adjuvants), have hydrophobic domains from which their surface-active properties arise (Hunter et al., 1995). Quil A has been used successfully for veterinary applications (Dalsgaard, 1987). It is a natural product composed of more than 23 different saponins and is generally considered too toxic for human use. In addition to severe local reactions and granulomas, toxicity includes severe haemolysis reflecting the affinity of saponins for cholesterol present in erythrocyte membranes, resulting in membrane solubilization and haemolysis (Kensil et al., 1991; Warren and Chedid, 1988; Dalsgaard, 1987).
Kensil et al.(1991) further tested separated fractions, finding decreased toxicity associated with QS-7 and QS-21 fractions. Increased antigen specific IgG responses were observed in mice intradermally vaccinated with antigen and 20 μg of QS-7, QS-17, QS-18, or QS-21, compared to antigen alone. QS-21 is less toxic than Quil A itself (Kensil et al., 1995).
QS-21 has been shown to be a potent adjuvant for CTL induction, and induces Th1 cytokines (IL-2 and IFN-γ) and antibodies of the IgG2a isotype (Kensil, 1996). While according to Evans et al.(2001), in a trial with HIV-1 env antigen, QS-21 was able to allow a significant dose reduction for the antigen and also enhanced proliferative T-cell responses but not CTL. QS-21 has also been claimed to perform as an adjuvant for DNA vaccines, following both systemic and mucosal administration (Sasaki et al., 1998).
However, ascribed to high toxicity, haemolytic effect and instability, Quillaja saponins have been restricted for use in human vaccination (Marciani et al., 2000; 2001; Liu et al., 2002).
Ginseng
Ginseng is another example of a saponin containing plant which is the best known traditional Chinese medicine. The major constituents of ginseng are the saponins (Wang et al., 1979). Sapogenins have been identified from the ginseng plant and have been extracted from its root (Jin, 1996). Ginseng extract has been reported to have modulatory effects on phagocytic cells, lymphocytes and antibody production in humans and animals. Increase in the human immune responses was reported by Scaglione et al.(1990), after oral administration of ginseng extract. Wu et al.(1991) reported that ginseng extract enhanced the proliferative response of human blood lymphocytes to phytohemagglutinin (PHA) at lower concentrations, but inhibited the response at higher concentration. Ginseng extract has potential as a stimulator of the immune system of dairy cows and treatment can activate the innate immunity of cows and may contribute to the cow’s recovery from mastitis (Hu et al., 2001). Ginseng extract influenced the zymosan-induced chemiluminescence (CL) in the blood in a dose dependent manner and significant increase of CL in milk was also seen for the cell treated with 102 μg/ml ginseng solution in comparison with control. A significantly higher proportion of phagocytic cells in blood were also recorded in ginseng treated group (Hu et al., 1995). Oral administration of ginseng extract has been found to enhance the antibody response and blood lymphocyte proliferation in human (Scaglione et al., 1990; Wu et al., 1991). A double blind clinical trial conducted by Scaglione et al.(1990) revealed that blood polymorphonuclear leukocytes (PMNL) phagocytosis and intracellular killing were significantly increased by the administration of 100 mg of an aqueous ginseng extract or standardized ginseng extract (G115) twice daily for 8 weeks. Ginsenoside Rg1 has been found to increase the lymphocyte proliferative responses to mitogenic stimulation and IL-2 production in aged rats but not in young rats (Liu and Zhang, 1995; 1996) and human (Liu et al., 1995).
Ginseng extract has also been reported to enhance, specific antibody response against diphtheric toxoids in mice (Yang et al., 1983); increase IgG and IgM antibody responses in mice immunized with sheep red blood cells and oral administration of ginseng extract at the same time (Jie et al., 1984). Sun et al.(2006a) reported the ovalbumin (OVA) specific IgG, IgG1, IgG2a and IgG2b antibody levels in serum were significantly enhanced by seven PTS from the root of Panax notoginseng compared with OVA control group (P<0.01 or P<0.001). The Rb1 fraction of ginseng elicits a balanced Th1 and Th2 immune response. In a study conducted by Rivera et al.(2005), porcine parvovirus (PPV) vaccines containing Rb1 was evaluated for inducing Th1 or Th2 type of immunity in mice. Study revealed the production of large amounts of cytokines including IFN-gamma, IL-2, IL-4, IL-10 and TNF-alpha and stimulated titers of antigen specific IgG1, IgG(2a) and IgG(2b). Smolina et al.(2001) reported that administration of the root or culture of Panax ginseng plant in mice increased PMNL and macrophage phagocytosis, and induced production of IFN-γ and TNF. Wang et al.(2001) found that an aqueous extract containing mainly oligosaccharides and polysaccharides from Panax quinquefolium stimulated the proliferation of normal mouse spleen cells, of which the major responding subpopulation was identified as B-lymphocytes. Sun et al.(2006b) reported that Panax notoginseng saponin could reduce leukocyte adhesion in venules under the inhibitory effect on the expression of adhesion molecules (CD11b and CD18) on neutrophils.
Immunostimulating complex (ISCOM)
These are comprised of antigen, cholesterol, phospholipid and saponin. ISCOM-based vaccines have been shown to promote both antibody and cellular immune responses in a variety of experimental animal models (Sanders et al., 2005). Quillaja saponins can combine with lipids and antigens to form ISCOM, which compose antigen and adjuvant in the same particle and have unique adjuvant properties (Morein et al., 1984; Lovgren et al., 1987).
ISCOMs have been reported to induce antibody responses or protective immunity in guinea-pig, turkey, cat, rabbit, dog, seal, sheep, pig, cow, horse or monkeys (Mowat et al., 1999) and induced specific CTL responses (Coulter et al., 1998). Cholera toxin A1 (CTA1-DD) and an unrelated antigen can be incorporated together into the ISCOM, resulting in greatly augmented immunogenicity of the antigen. The combined vector was a highly effective enhancer of a broad range of immune responses, including specific serum Abs and balanced Th1 and Th2 CD4(+) T cell priming as well as a strong mucosal IgA response (Helgeby et al., 2006). To study responses generated by nasal vaccination with an ISCOM-based vaccine for equine influenza (EQUIP F) in horses revealed that significantly enhanced levels of virus-specific IgA were detected in the nasal washes from vaccinated ponies (Crouch et al., 2005).
Astragalus saponin
Astragalus (huang qi), a Chinese traditional herb, is thought to strengthen and boost the immune system by improving the ability of the macrophages. It contains numerous triterpene saponins (astragalosides I~X, isoastragalosides I~IV and soyasaponin I). Most of the modern research on astragalus has focused on its immune-enhancing effects. Laboratory studies have found astragalus to increase macrophages, T-cell transformation, NK cell activity, interferon production, and phagocytosis. The study also documented increased levels of IgA and IgG antibodies in nasal secretions after two months of treatment (Chang and But, 1986).
Astragalus saponin is believed to induce the cellular and humoral immune responses with slight hemolytic activity. Yang et al.(2005) reported very low haemolytic effect (0.66%) with 500 µg/ml concentration of Astragalus membranaceus saponins (AMS) induced in mice and significantly enhanced OVA-specific IgG, IgG1 and IgG2b antibody titers in mice serum. Peripheral lymphocyte proliferation and serum antibody titer increased in chicken vaccinated with Newcastle disease have also been found (Kong et al., 2004). A ten-fold potentiation in the in vitro antitumor activity of rIL-2 generated lymphokine-activated killer (LAK) cells was recorded by Wang et al.(1992). Astragalus was shown to potentiate the LAK cell inducing activity of rIL-2 against an Hs294T melanoma cell line. Fifty U/ml of rIL-2 with Astragalus extract F3 was more effective than 500 U/ml rIL-2 alone (Chu et al., 1994).
Yesilada et al.(2005) studied the effect of 13 cycloartane- and 1 oleanan-type triterpene saponins isolated from Turkish species included Astragalus brachypterus, Astragalus cephalotes, Astragalus microcephalus, and Astragalus trojanus, as well as methanol extracts from the roots of three Astragalus cephalotes, Astragalus oleifolius and Astragalus trojanus on in vitro cytokine release. All triterpene saponins tested showed a prominent IL-2 inducing activity between 35.9% and 139.6%. Among the extracts the highest score was obtained for Astragalus oleifolius (141.2%).
Astragalus herbal mixture stimulated macrophages to produce interleukin-6 and tumor necrosis factor (Yoshida et al., 1997).
Others
The root of a herbaceous plant Achyranthes bidentata (Amaranthaceae family) (“Niu Xi” in Chinese, Radix Achyranthes Bidentatae) is a well-known traditional Chinese medicine containing saponins (Wang and Zhu, 1996; Li et al., 2005) and has been reported as immunostimulator (Li et al., 2003; Chen et al., 2005). Achyranthes bidentata saponins (ABS) modulated immune responses and the haemolytic activities have been observed in mice. ABS significantly enhanced the OVA-specific IgG, IgG1, IgG2b antibody titers with slight haemolysis in mice (Sun, 2006).
Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham) represent a new class of plant stress metabolites capable of activating stress adaptation and suppressing proinflammatory components of the innate immune system in human cells by redox regulation (Haridas et al., 2004).
Saponins from soybean have been separated into six (Khalil and El-Adawy, 1994) or eight (Oda et al., 2003) fractions of soyasapogenol and soyasaponins groups. Oda et al.(2000; 2003) found that the soyasaponins exhibited high adjuvant activity while the soyasapogenol group exhibited low activity. Soyasaponin also exhibited low hemolytic activity.
Codonopsis (Codonopsis pilosula, dang shen) is a less expensive, milder substitute for Asian ginseng and contains saponins. Its uses are similar to those of Asian ginseng, with laboratory experiments having shown that codonopsis may enhance phagocytosis of the reticuloendothelial system, thus improving immune system function (Steven and Yue, 1992).
Footnotes
Project (No. 2004C32047) supported by the Department of Science and Technology of Zhejiang Province, China
References
- 1.Allison A. Mode of action of immunological adjuvants. J Reticuloendothel Soc. 1979;26(Suppl.):619–630. [PubMed] [Google Scholar]
- 2.Allison AC, Byars NE. Immunological adjuvants: desirable properties and side-effects. Mol Immunol. 1991;28(3):279–284. doi: 10.1016/0161-5890(91)90074-T. [DOI] [PubMed] [Google Scholar]
- 3.Bangham AD, Horne RW, Glauert AM, Dingle JT, Lucy JA. Action of saponins on biological membranes. Nature. 1962;196(4858):952–955. doi: 10.1038/196952a0. [DOI] [PubMed] [Google Scholar]
- 4.Barr IG, Sjolander A, Cox JC. ISCOMs and other saponin based adjuvants (review) Adv Drug Deliv Rev. 1998;32(3):247–271. doi: 10.1016/S0169-409X(98)00013-1. [DOI] [PubMed] [Google Scholar]
- 5.Bomford R. Will Adjuvants be Needed for Vaccines of the Future? In: Brown F, Haaheim LR, editors. Modulation of the Immune Response to Vaccine Antigens, Vol. 92. Basel, Karger: Development in Biological Standardization; 1998. pp. 13–17. [PubMed] [Google Scholar]
- 6.Bomford R, Stapleton M, Winsor S, Beesley JE, Jessup EA, Price KR, Fenwick GR. Adjuvanticity and ISCOM formation by structurally diverse saponins. Vaccine. 1992;10(9):572–577. doi: 10.1016/0264-410X(92)90435-M. [DOI] [PubMed] [Google Scholar]
- 7.Bowersock TL, Martin S. Vaccine delivery to animals. Adv Drug Deliv Rev. 1999;38(2):167–194. doi: 10.1016/S0169-409X(99)00015-0. [DOI] [PubMed] [Google Scholar]
- 8.Byars NE, Allison AC. Immunologic Adjuvants: General Properties, Advantages, and Limitations. In: Zola H, editor. Laboratory Methods in Immunology. Boca Raton: CRC Press; 1990. pp. 39–51. [Google Scholar]
- 9.Chang HM, But PP. Pharmacology and Applications of Chinese Materia Medica, Vol. 1. Singapore: World Scientific; 1986. p. 1041. [Google Scholar]
- 10.Chavali SR, Campbell JB. Immunomodulatory effects of orally-administered saponins and nonspecific resistance against rabies infection. Int Arch Allergy Appl Immunol. 1987;84(2):129–134. doi: 10.1159/000234411. [DOI] [PubMed] [Google Scholar]
- 11.Chavali SR, Campbell JB. Adjuvant effects of orally administered saponins on humoral and cellular immune responses in mice. Immunobiology. 1987;174(3):347–359. doi: 10.1016/s0171-2985(87)80009-8. [DOI] [PubMed] [Google Scholar]
- 12.Chavali SR, Francis T, Campbell JB. An in-vitro study of immunomodulatory effects of some saponins. Int J Immunopharmacol. 1987;9(6):675–684. doi: 10.1016/0192-0561(87)90038-5. [DOI] [PubMed] [Google Scholar]
- 13.Chen XM, Xu YJ, Tian GY. Physical-chemical properties and structure elucidation of abPS isolated from the root of Achyranthes bidentata . Acta Pharm Sin. 2005;40(1):32–35. [PubMed] [Google Scholar]
- 14.Chu DT, Lin JR, Wong W. The in vitro potentiation of LAK cell cytotoxicity in cancer and AIDS patients induced by F3-a fractionated extract of Astragalus membranaceus . Chin J Oncol. 1994;16(3):167–171. [PubMed] [Google Scholar]
- 15.Cohen J, Marshall E. Bioterrorism. Vaccines for biodefense: a system in distress. Science. 2001;294(5542):498–501. doi: 10.1126/science.294.5542.498. [DOI] [PubMed] [Google Scholar]
- 16.Cossarini-Dunier M. Effect of different adjuvants on the humoral immune response of rainbow trout. Dev Comp Immunol. 1985;9(1):141–146. doi: 10.1016/0145-305X(85)90067-9. [DOI] [PubMed] [Google Scholar]
- 17.Coulter A, Wong TY, Drane D, Bates J, Macfarlan R, Cox J. Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes Iscoms (T.M.) and oil-in-water vaccines. Vaccine. 1998;16(11/12):1243–1253. doi: 10.1016/S0264-410X(98)80125-4. [DOI] [PubMed] [Google Scholar]
- 18.Cox JC, Coulter AR. Advances in Adjuvant Technology and Application. In: Yong WK, editor. Animal Parasite Control Utilizing Bio-technology. Boca Raton: CRC Press; 1992. pp. 49–112. [Google Scholar]
- 19.Cox JC, Coulter AR. Adjuvants–a classification and review of their modes of action. Vaccine. 1997;15(3):248–256. doi: 10.1016/S0264-410X(96)00183-1. [DOI] [PubMed] [Google Scholar]
- 20.Crouch CF, Daly J, Henley W, Hannant D, Wilkins J, Francis MJ. The use of a systemic prime/mucosal boost strategy with an equine influenza ISCOM vaccine to induce protective immunity in horses. Vet Immunol Immunopathol. 2005;108(3-4):345–355. doi: 10.1016/j.vetimm.2005.06.009. [DOI] [PubMed] [Google Scholar]
- 21.Curtiss R. Bacterial infectious disease control by vaccine development. J Clin Invest. 2002;110(8):1061–1066. doi: 10.1172/JCI200216941. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Dalsgaard K. Adjuvants. Vet Immunol Immunopathol. 1987;17(1-4):145–152. doi: 10.1016/0165-2427(87)90135-8. [DOI] [PubMed] [Google Scholar]
- 23.de Oliveira CAC, Perez AC, Merino G, Prieto JG, Alvarez AI. Protective effects of Panax ginseng on muscle injury and inflammation after eccentric exercise. Comp Biochem Physiol. 2001;130(3):369–377. doi: 10.1016/s1532-0456(01)00262-9. [DOI] [PubMed] [Google Scholar]
- 24.Delmas F, Di Giorgio C, Elias R, Gasquet M, Azas N, Mshvildadze V, Dekanosidze G, Kemertelidze E, Timon-David P. Antileishmanial activity of three saponins isolated from ivy, alpha-hederin, beta-hederin and hederacolchiside A(1), as compared with their action on mammalian cells cultured in vitro. Planta Medica. 2000;66(4):343–347. doi: 10.1055/s-2000-8541. [DOI] [PubMed] [Google Scholar]
- 25.Edelman R. Adjuvants for the Future. In: Levine MM, Woodrow GC, Kaper JB, et al., editors. New Generation Vaccines. New York: Marcel Deker Inc; 1997. pp. 173–192. [Google Scholar]
- 26.Evans TG, McElrath MJ, Matthews T, Montefiori D, Weinhold K, Wolff M, Keefer MC, Kallas EG, Corey L, Gorse GJ, et al. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine. 2001;19(15-16):2080–2091. doi: 10.1016/S0264-410X(00)00415-1. [DOI] [PubMed] [Google Scholar]
- 27.Fearon DT. Seeking wisdom in innate immunity. Nature. 1997;388(6640):323–324. doi: 10.1038/40967. [DOI] [PubMed] [Google Scholar]
- 28.Fenwick GR, Price KR, Tsukamoto C, et al. Saponins. In: Mello FJPD, Duffus CM, Duffus JH, editors. Saponins in Toxic Substances in Crop Plants. Cambridge: The Royal Society of Chemistry; 1991. pp. 285–327. [Google Scholar]
- 29.Francis G, Kerem Z, Makkar HPS, Becker K. The biological action of saponins in animal system: a review. Br J Nutr. 2002;88(6):587–605. doi: 10.1079/BJN2002725. [DOI] [PubMed] [Google Scholar]
- 30.Gong XM, Wu YZ. Research actuality and tendency of immune adjuvant. Chin J Vet Drug. 1996;1:41–44. [Google Scholar]
- 31.Grayson TH, Williams RJ, Wrathmell AB, Munn CB, Harris JE. Effects of immunopotentiating agents on the immune response of rainbow trout, Salmo gairdneri Richardson, to ERM vaccine. J Fish Biol. 1987;31(sa):195–202. doi: 10.1111/j.1095-8649.1987.tb05313.x. [DOI] [Google Scholar]
- 32.Gupta RK. Aluminum compounds as a vaccine adjuvants. Adv Drug Deliv Rev. 1998;32(3):155–172. doi: 10.1016/S0169-409X(98)00008-8. [DOI] [PubMed] [Google Scholar]
- 33.Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. Adjuvants–a balance between toxicity and adjuvanticity. Vaccine. 1993;11(3):293–306. doi: 10.1016/0264-410X(93)90190-9. [DOI] [PubMed] [Google Scholar]
- 34.Gupta RK, Rost BE, Relyveld E, Siber GR. Adjuvant properties of aluminum and calcium compounds. Pharm Biotechnol. 1995;6:229–248. doi: 10.1007/978-1-4615-1823-5_8. [DOI] [PubMed] [Google Scholar]
- 35.Haridas V, Arntzen CJ, Gutterman JU. Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), inhibit activation of nuclear factor-kappa B by inhibiting both its nuclear localization and ability to bind DNA. Proc. Natl. Acad. Sci. USA. 2001;98(20):11557–11562. doi: 10.1073/pnas.191363498. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Haridas V, Hanausek M, Nishimura G, Soehnge H, Gaikwad A, Narog M, Spears E, Zoltaszek R, Walaszek Z, Gutterman JU. Triterpenoid electrophiles (avicins) activate the innate stress response by redox regulation of a gene battery. J Clin Invest. 2004;113(1):65–73. doi: 10.1172/JCI200418699. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Helgeby A, Robson NC, Donachie AM, Beackock-Sharp H, Lovgren K, Schon K, Mowat A, Lycke NY. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells. J Immunol. 2006;176(6):3697–3706. doi: 10.4049/jimmunol.176.6.3697. [DOI] [PubMed] [Google Scholar]
- 38.Hu S, Concha C, Cooray R, Holmberg O. Ginseng enhanced oxidative and phagocytic activities of polymorphonulear leukocytes from bovine peripheral blood and stripping milk. Vet Res. 1995;26(3):155–161. [PubMed] [Google Scholar]
- 39.Hu S, Concha C, Johannisson A, Meglia G, Waller KP. Effect of subcutaneous injection of ginseng on cows with sub-clinical Staphylococcus aureus mastitis. J Vet Med Sci B. 2001;48(7):519–528. doi: 10.1046/j.1439-0450.2001.00470.x. [DOI] [PubMed] [Google Scholar]
- 40.Hunter RL, Olsen MR, Bennett B. Copolymer Adjuvants and TiterMax®. In: Stewart-Tull DES, editor. The Theory and Practical Application of Adjuvants. New York: Wiley; 1995. pp. 51–94. [Google Scholar]
- 41.Jacobsen NE, Fairbrother WJ, Kensil CR, Lim A, Wheeler DA, Powell MF. Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy. Carbohydr Res. 1996;280(1):1–14. doi: 10.1016/0008-6215(95)00278-2. [DOI] [PubMed] [Google Scholar]
- 42.Jennings R, Simms JR, Heath AW. Adjuvants and Delivery Systems for Viral Vaccines-Mechanisms and Potential. In: Brown F, Haaheim LR, editors. Modulation of the Immune Response to Vaccine Antigens, Vol. 92. Basel, Karger: Development in Biological Standardization; 1998. pp. 19–28. [PubMed] [Google Scholar]
- 43.Jie YH, Cammisuli S, Baggliolini M. Immuno-modulatory effects of Panax ginseng CA Meyer in the mouse. Agents Actions. 1984;15(3-4):386–391. doi: 10.1007/BF01972376. [DOI] [PubMed] [Google Scholar]
- 44.Jin CD. Advances on analytical methods of the chemical constituents of ginseng. Chin Herb Med. 1996;27:631–633. [Google Scholar]
- 45.Kaeberle ML. Functions of Current Adjuvants in Induction of Immune Response. In: Nervig RM, Gough PM, Kaeberle ML, et al., editors. Advances in Carriers and Adjuvants for Veterinary Biologics. Ames, IA: Iowa State University Press; 1986. pp. 11–24. [Google Scholar]
- 46.Kensil CR. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst. 1996;13(1-2):1–55. [PubMed] [Google Scholar]
- 47.Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja-saponaria molina cortex. J Immunol. 1991;146(2):431–437. [PubMed] [Google Scholar]
- 48.Kensil CR, Wu JY, Soltysik S. Structural and Immunological Characterization of the Vaccine Adjuvant QS-21. In: Powell MF, Newman MJ, editors. Vaccine Design. The Subunit and Adjuvant Approach. New York: Plenum Press; 1995. pp. 525–541. [DOI] [PubMed] [Google Scholar]
- 49.Khalil AH, El-Adawy TA. Isolation, identification and toxicity of saponin from different legumes. Food Chem. 1994;50(2):197–201. doi: 10.1016/0308-8146(94)90120-1. [DOI] [Google Scholar]
- 50.Kong X, Hu Y, Rui R, Wang D, Li X. Effects of Chinese herbal medicinal ingredients on peripheral lymphocyte proliferation and serum antibody titer after vaccination in chicken. Int Immunopharmacol. 2004;4(7):975–982. doi: 10.1016/j.intimp.2004.03.008. [DOI] [PubMed] [Google Scholar]
- 51.Lacaille-Dubois MA, Hanquet B, Cui ZH, Lou ZC, Wagner H. A new biologically active acylated triterpene saponin from Silene fortunei . J Nat Prod. 1999;62(1):133–136. doi: 10.1021/np980172y. [DOI] [PubMed] [Google Scholar]
- 52.Li CC, Hu XG, Zhang WX, Xie LW, Zhang HY, Dong L, Cai XH, Wu RX, Zhang ZX, He QS. Eosinophils apoptosis, fas mRNA and bcl-2 mRNA expressions in asthma model of young rat and effects of Achyranthes bidentata polysaccharides. Chin J Pediatr. 2003;41(9):657–660. [PubMed] [Google Scholar]
- 53.Li JX, Hareyama T, Tezuka Y, Zhang Y, Miyahara T, Kadota S. Five new oleanolic acid glycosides from Achyranthes bidentata with inhibitory activity on osteoclast formation. Planta Med. 2005;71(7):673–679. doi: 10.1055/s-2005-871275. [DOI] [PubMed] [Google Scholar]
- 54.Liu M, Zhang J. Stimulatory effect of ginsenosides Rg1 aged rats. Yao Xue Bao. 1995;30:818–823. (in Chinese) [PubMed] [Google Scholar]
- 55.Liu M, Zhang J. Studies on the mechanisms of immunoregulatory effects of ginsenosides Rg1 in aged rats. Yao Xue Bao. 1996;31:95–100. (in Chinese) [PubMed] [Google Scholar]
- 56.Liu J, Wang S, Liu H, Yang L, Nan G. Stimulatory effect on saponin from Panax ginseng on immune function of lymphocytes in the elderly. Mech Ageing Dev. 1995;83(1):43–53. doi: 10.1016/0047-6374(95)01618-A. (in Chinese) [DOI] [PubMed] [Google Scholar]
- 57.Liu G, Anderson C, Scaltreto H, Barbon J, Kensil CR. QS-21 structure/function studies: effect of acylation on adjuvant activity. Vaccine. 2002;20(21-22):2808–2815. doi: 10.1016/S0264-410X(02)00209-8. [DOI] [PubMed] [Google Scholar]
- 58.Lovgren K, Lindmark J, Pipkorn R, Morein B. Antigen presentation of small molecules and synthetic peptides conjugated to a performed ISCOM as carrier. J Immunol Meth. 1987;98(1):137–143. doi: 10.1016/0022-1759(87)90447-9. [DOI] [PubMed] [Google Scholar]
- 59.Marciani DJ, Press JB, Reynolds RC. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine. 2000;18(27):3141–3151. doi: 10.1016/S0264-410X(00)00118-3. [DOI] [PubMed] [Google Scholar]
- 60.Marciani DJ, Pathak AK, Reynolds RC, Seitz L, May RD. Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins. Int Immunopharmacol. 2001;1(4):813–818. doi: 10.1016/S1567-5769(01)00016-9. [DOI] [PubMed] [Google Scholar]
- 61.McElrath MJ. Selection of potent immunological adjuvants for vaccine construction. Semin Cancer Biol. 1995;6(6):375–385. doi: 10.1016/1044-579X(95)90007-1. [DOI] [PubMed] [Google Scholar]
- 62.Morein B, Sundquist B, Höglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature. 1984;308(5958):457–460. doi: 10.1038/308457a0. [DOI] [PubMed] [Google Scholar]
- 63.Mowat AM, Donachie AM, Reid G, Jarrett O. Immune-stimulating complexes containing Quil A and protein antigen prime Class I MHC-restricted T lymphocytes in-vivo and are immunogenic by the oral route. Immunology. 1991;72(3):317–322. [PMC free article] [PubMed] [Google Scholar]
- 64.Mowat AM, Smith RE, Donachie AM, Furrie E, Grdic D, Lycke N. Oral vaccination with immune stimulating complexes. Immunol Lett. 1999;65(1-2):133–140. doi: 10.1016/S0165-2478(98)00136-9. [DOI] [PubMed] [Google Scholar]
- 65.Oda K, Matsuda H, Murakami T, Katayama S, Ohgitani T, Yoshikawa M. Adjuvant and haemolytic activities of 47 saponins derived from medicinal and food plants. Biol Chem. 2000;381(1):67–74. doi: 10.1515/BC.2000.009. [DOI] [PubMed] [Google Scholar]
- 66.Oda K, Matsuda H, Murakami T, Katayama S, Ohgitani T, Yoshikawa M. Relationship between adjuvant activity and amphipathic structure of soyasaponins. Vaccine. 2003;21(17-18):2145–2151. doi: 10.1016/S0264-410X(02)00739-9. [DOI] [PubMed] [Google Scholar]
- 67.Plohmann B, Bader G, Hiller K, Franz G. Immunomodulatory and antitumoral effects of triterpenoid saponins. Pharmazie. 1997;52(12):953–957. [PubMed] [Google Scholar]
- 68.Riguera R. Isolating bioactive compounds from marine organisms. J Marine Biotechnol. 1997;5:187–193. [Google Scholar]
- 69.Rivera E, Ekholm PF, Inganas M, Paulie S, Gronvik KO. The Rb1 fraction of ginseng elicits a balanced Th1 and Th2 immune response. Vaccine. 2005;23(46-47):5411–5419. doi: 10.1016/j.vaccine.2005.04.007. [DOI] [PubMed] [Google Scholar]
- 70.Ronnberg B, Fekadu M, Behboudi S, Kenne L, Morein B. Effects of carbohydrate modification of Quillaja saponaria Molina QH-B fraction on adjuvant activity, cholesterolbinding capacity and toxicity. Vaccine. 1997;15(17-18):1820–1826. doi: 10.1016/S0264-410X(97)00139-4. [DOI] [PubMed] [Google Scholar]
- 71.Sanders MT, Brown LE, Deliyannis G, Pearse MJ. ISCOM-based vaccines: the second decade. Immunol Cell Biol. 2005;83(2):119–128. doi: 10.1111/j.1440-1711.2005.01319.x. [DOI] [PubMed] [Google Scholar]
- 72.Sasaki S, Sumino K, Hamajima K, Fukushima J, Ishii N, Kawamoto S, Mohri H, Kensil CR, Okuda K. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J Virol. 1998;72(6):4931–4939. doi: 10.1128/jvi.72.6.4931-4939.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Scaglione F, Ferrara F, Dugnani S, Falchi M, Santoro G, Fraschini F. Immunomodulatory effects of two extracts of Panax ginseng C.A. Meyer. Drugs Exp Clin Res. 1990;16(10):537–542. [PubMed] [Google Scholar]
- 74.Singh M, O′Hagan DT. Invited review recent advances in veterinary vaccine adjuvants. Int J Parasitol. 2003;33(5-6):469–478. doi: 10.1016/S0020-7519(03)00053-5. [DOI] [PubMed] [Google Scholar]
- 75.Sjölander A, Drane D, Maraskovsky E, Scheerlinck J, Suhrbier A, Tennent J, Pearse M. Immune responses to ISCOM formulations in animal and primate models. Vaccine. 2001;19(17-19):2661–2665. doi: 10.1016/S0264-410X(00)00497-7. [DOI] [PubMed] [Google Scholar]
- 76.Smolina TP, Solov′eva TF, Besednova NN. Immunotropic activity of panaxans-bioglycans isolated from ginseng. Antibiot Khimioter. 2001;46(7):19–22. (in Russian) [PubMed] [Google Scholar]
- 77.So HS, Yoon HS, Kwoon YS, Sung JH, Lee TG, Park EN, Cho HS, Lee BM, Cho JM, Ryu WS. Effect of a novel saponin adjuvant derived from Quillaja saponaria on immune response to recombinant hepatitis B surface antigen. Mol Cells. 1997;7(2):178–186. [PubMed] [Google Scholar]
- 78.Steven F, Yue C. Herbal Emissaries: Bringing Chinese Herbs to the West: A Guide to Gardening, Herbal Wisdom, and Well-Being. Rochester, VT: Healing Arts Press; 1992. p. 61. [Google Scholar]
- 79.Sun HX. Adjuvant effect of Achyranthes bidentata saponins on specific antibody and cellular response to ovalbumin in mice. Vaccine. 2006;24(17):3432–3439. doi: 10.1016/j.vaccine.2006.02.014. [DOI] [PubMed] [Google Scholar]
- 80.Sun H, Yang Z, Ye Y. Structure and biological activity of protopanaxatriol-type saponins from the roots of Panax notoginseng . Int Immunopharmacol. 2006;6(1):14–25. doi: 10.1016/j.intimp.2005.07.003. [DOI] [PubMed] [Google Scholar]
- 81.Sun K, Wang CS, Guo J, Liu YY, Wang F, Liu LY, He JG, Fan JY, Han JY. Effect of Panax notoginseng saponins on lipopolysaccharide-induced adhesion of leukocytes in rat mesenteric venules. Clin Hemorheol Microcirc. 2006;34(1-2):103–108. [PubMed] [Google Scholar]
- 82.Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky JA. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature. 1990;344(6269):873–875. doi: 10.1038/344873a0. [DOI] [PubMed] [Google Scholar]
- 83.Vogel FR. Immunologic adjuvants for modern vaccine formulations. Ann NY Acad Sci. 1995;754(1 combined vacc):153–160. doi: 10.1111/j.1749-6632.1995.tb44448.x. [DOI] [PubMed] [Google Scholar]
- 84.Vogel FR. Adjuvants in Perspective. In: Brown F, Haaheim LR, editors. Modulation of the Immune Response to Vaccine Antigens, Vol. 92. Basel, Karger: Development in Biological Standardization; 1998. pp. 241–248. [PubMed] [Google Scholar]
- 85.Vogel FR, Powell MF. A Compendium of Vaccine Adyuvantes and Excipients. In: Powell MF, Neuman MJ, editors. Vaccine Design, the Subunit and Adyuvant Approach. New York: Plenum Press; 1995. pp. 141–228. [Google Scholar]
- 86.Wang XJ, Zhu LZ. Studies on the saponin constituents of Niuxi (Achyrathes Bidentata) J Fourth Mil Med Univ. 1996;17(6):427–430. [Google Scholar]
- 87.Wang MZ, Gao FY, Zhang GD, Zhang SR. Analysis of ginseng. Acta Pharm Sin. 1979;14(5):309–315. (in Chinese) [PubMed] [Google Scholar]
- 88.Wang Y, Qian XJ, Hadley HR, Lau BH. Phytochemicals potentiate interleukin-2 generated lymphokine-activated killer cell cytotoxicity against murine renal cell carcinoma. Mol Biother. 1992;4(3):143–146. [PubMed] [Google Scholar]
- 89.Wang M, Guilbert LJ, Ling L, Li J, Wu Y, Xu S, Pang P, Shan JJ. Immunomodulating activity of CTV-E002, a proprietary extract from North American ginseng (Panax equinquefolium) J Pharm Pharmacol. 2001;53(11):1515–1523. doi: 10.1211/0022357011777882. [DOI] [PubMed] [Google Scholar]
- 90.Warren HS, Chedid LA. Future prospects for vaccine adjuvants. Crit Rev Immunol. 1988;8(2):83–101. [PubMed] [Google Scholar]
- 91.Wu S, Hua ZJ, Xio YL, Wang Y. Effect of Ginsengopolypeptide on the 3H-TdR integration of human blood lymphocyte. Chin Med J. 1991;104(5):399–401. [PubMed] [Google Scholar]
- 92.Yang GZ, Bao T, Fu N, Gen PL. A preliminary study on the immunomodulatory effects of ginseng saponins in vitro and in vivo. J Norman Bethune Univ Med Sci. 1983;9:1–7. [Google Scholar]
- 93.Yang ZG, Sun HX, Fang WH. Haemolytic activities and adjuvant effect of Astragalus membranaceus saponins (AMS) on the immune responses to ovalbumin in mice. Vaccine. 2005;23(44):5196–5203. doi: 10.1016/j.vaccine.2005.06.016. [DOI] [PubMed] [Google Scholar]
- 94.Yesilada E, Bedir E, Calis I, Takaishi Y, Ohmoto Y. Effects of triterpene saponins from Astragalus species on in vitro cytokine release. J Ethnopharmacol. 2005;96(1-2):71–77. doi: 10.1016/j.jep.2004.08.036. [DOI] [PubMed] [Google Scholar]
- 95.Yoshida Y, Wang MQ, Shan BE, Yamashita U. Immunomodulating activity of Chinese medical herbs and Oldenlandia diffusa in particular. Int J Immunopharmacol. 1997;19(7):359–370. doi: 10.1016/S0192-0561(97)00076-3. [DOI] [PubMed] [Google Scholar]
- 96.Yoshiki Y, Kudou S, Okubo K. Relationship between chemical structures and biological activities of triterpenoid saponins from soybean (review) Biosci Biotechnol Biochem. 1998;62(12):2291–2299. doi: 10.1271/bbb.62.2291. [DOI] [PubMed] [Google Scholar]
- 97.Yui S, Ubukata K, Hodono K, Kitahara M, Mimaki Y, Kuroda M, Sashida Y, Yamazaki M. Macrophage-oriented cytotoxic activity of novel triterpene saponins extracted from roots of Securidaca inappendiculata . Int Immunopharmacol. 2001;1(11):1989–2000. doi: 10.1016/S1567-5769(01)00126-6. [DOI] [PubMed] [Google Scholar]